The -94Ins/DelATTG polymorphism in NFκB1 promoter modulates chronic hepatitis C and liver disease progression

Infection, Genetics and Evolution

Volumn 39, Issue , 2016, Pages 141-146

  Fakhir, Fatima Zohra ^a,b   Lkhider, Mustapha ^c   Badre, Wafaa ^d   Alaoui, Rhimou ^d   Pineau, Pascal ^e   Ezzikouri, Sayeh ^a   Benjelloun, Soumaya ^a  

^a Institut Pasteur du Maroc   (Morocco)

^b FACULTÉ DES SCIENCES   (Morocco)

^c HASSAN II UNIVERSITY OF CASABLANCA   (Morocco)

^d IBN ROCHD UNIVERSITY HOSPITAL   (Morocco)

^e INSTITUT PASTEUR   (France)

Author keywords

Hepatitis C Virus; Hepatocellular carcinoma; Inflammation; I B; NF B

Indexed keywords

I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF KAPPA B1; UNCLASSIFIED DRUG; I KAPPA B; NFKB1 PROTEIN, HUMAN; NFKBIA PROTEIN, HUMAN;

3' UNTRANSLATED REGION; ADULT; ALLELE; ARTICLE; CASE CONTROL STUDY; CHRONIC HEPATITIS C; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; AGED; CARCINOMA, HEPATOCELLULAR; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; INDEL MUTATION; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; STATISTICAL MODEL; VIROLOGY;

AGED; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS C, CHRONIC; HUMANS; I-KAPPA B PROTEINS; INDEL MUTATION; LIVER CIRRHOSIS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; PROMOTER REGIONS, GENETIC;

EID: 84956616070     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2016.01.023     Document Type: Article

References (36)

1. Alter M.J. Epidemiology of hepatitis C. Hepatology 1997, 26:62S-65S.
2. Arsura M., Mercurio F., Oliver A.L., Thorgeirsson S.S., Sonenshein G.E. Role of the IkappaB kinase complex in oncogenic Ras- and Raf-mediated transformation of rat liver epithelial cells. Mol. Cell. Biol. 2000, 20:5381-5391.
3. Baeuerle P.A. IkappaB-NF-kappaB structures: at the interface of inflammation control. Cell 1998, 95:729-731.
4. Bonizzi G., Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004, 25:280-288.
5. Brahim I., Akil A., Mtairag el M., Pouillot R., Malki A.E., Nadir S., Alaoui R., Njouom R., Pineau P., Ezzikouri S., Benjelloun S. Morocco underwent a drift of circulating hepatitis C virus subtypes in recent decades. Arch. Virol. 2012, 157:515-520.
6. Brown R.E., Tan D., Taylor J.S., Miller M., Prichard J.W., Kott M.M. Morphoproteomic confirmation of constitutively activated mTOR, ERK, and NF-kappaB pathways in high risk neuro-blastoma, with cell cycle and protein analyte correlates. Ann. Clin. Lab. Sci. 2007, 37:141-147.
7. Cheng C.W., Su J.L., Lin C.W., Su C.W., Shih C.H., Yang S.F., Chien M.H. Effects of NFκB1 and NFκBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS One 2013, 8.
8. Curran J.E., Weinstein S.R., Griffiths L.R. Polymorphic variants of NFκB1 and its inhibitory protein NFκBIA, and their involvement in sporadic breast cancer. Cancer Lett. 2002, 188:103-107.
9. Del Prete A., Allavena P., Santoro G., Fumarulo R., Corsi M.M., Mantovani A. Molecular pathways in cancer-related inflammation. Biochem. Med. (Zagreb) 2011, 21:264-275.
10. Elsharkawy A.M., Mann D.A. Nuclear factor-kappaB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007, 46:590-597.
11. Ezzikouri S., Alaoui R., Rebbani K., Brahim I., Fakhir F.Z., Nadir S., Diepolder H., Khakoo S.I., Thursz M., Benjelloun S. Genetic variation in the interleukin-28B gene is associated with spontaneous clearance and progression of hepatitis C virus in Moroccan patients. PLoS One 2013, 8.
12. Ezzikouri S., Alaoui R., Tazi S., Nadir S., Elmdaghri N., Pineau P., Benjelloun S. The adiponutrin I148M variant is a risk factor for HCV-associated liver cancer in North-African patients. Infect. Genet. Evol. 2014, 21:179-183.
13. Freeman R.B. Diagnosing hepatocellular carcinoma: a virtual reality. Liver Transpl. 2002, 8:762-764.
14. Gao J., Pfeifer D., He L.J., Qiao F., Zhang Z., Arbman G., Wang Z.L., Jia C.R., Carstensen J., Sun X.F. Association of NFκBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations. Scand. J. Gastroenterol. 2007, 42:345-350.
15. Gao J., Xu H.L., Gao S., Zhang W., Tan Y.T., Rothman N., Purdue M., Gao Y.T., Zheng W., Shu X.O., Xiang Y.B. Genetic polymorphism of NFκB1 and NFκBIA genes and liver cancer risk: a nested case-control study in Shanghai, China. BMJ Open 2014, 4.
16. Hoofnagle J.H. Course and outcome of hepatitis C. Hepatology 2002, 36:S21-S29.
17. Karban A.S., Okazaki T., Panhuysen C.I., Gallegos T., Potter J.J., Bailey-Wilson J.E., Silverberg M.S., Duerr R.H., Cho J.H., Gregersen P.K., Wu Y., Achkar J.P., Dassopoulos T., Mezey E., Bayless T.M., Nouvet F.J., Brant S.R. Functional annotation of a novel NFκB1 promoter polymorphism that increases risk for ulcerative colitis. Hum. Mol. Genet. 2004, 13:35-45.
18. Liang T.J., Rehermann B., Seeff L.B., Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 2000, 132:296-305.
19. May M.J., Ghosh S. Rel/NF-kappa B and I kappa B proteins: an overview. Semin. Cancer Biol. 1997, 8:63-73.
20. Miyamoto S., Verma I.M. Rel/NF-kappa B/I kappa B story. Adv. Cancer Res. 1995, 66:255-292.
21. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J., Sledge G.W. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell. Biol. 1997, 17:3629-3639.
22. Ribeiro P.S., Cortez-Pinto H., Sola S., Castro R.E., Ramalho R.M., Baptista A., Moura M.C., Camilo M.E., Rodrigues C.M. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am. J. Gastroenterol. 2004, 99:1708-1717.
23. Riemann K., Becker L., Struwe H., Rubben H., Eisenhardt A., Siffert W. Insertion/deletion polymorphism in the promoter of NFκB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int. J. Clin. Pharmacol. Ther. 2007, 45:423-430.
24. Robinson S.M., Mann D.A. Role of nuclear factor kappaB in liver health and disease. Clin. Sci. (Lond.) 2010, 118:691-705.
25. Sato Y., Kato J., Takimoto R., Takada K., Kawano Y., Miyanishi K., Kobune M., Sato Y., Takayama T., Matunaga T., Niitsu Y. Hepatitis C virus core protein promotes proliferation of human hepatoma cells through enhancement of transforming growth factor alpha expression via activation of nuclear factor-kappaB. Gut 2006, 55:1801-1808.
26. Senol Tuncay S., Okyay P., Bardakci F. Identification of NF-kappaB1 and NF-kappaBIAlpha polymorphisms using PCR-RFLP assay in a Turkish population. Biochem. Genet. 2010, 48:104-112.
27. Sonenshein G.E. Rel/NF-kappa B transcription factors and the control of apoptosis. Semin. Cancer Biol. 1997, 8:113-119.
28. Sun X.F., Zhang H. NFκB and NFκBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol. Histopathol. 2007, 22:1387-1398.
29. Tan S.C., Suzairi M.S., Aizat A.A., Aminudin M.M., Nurfatimah M.S., Bhavaraju V.M., Biswal B.M., Ankathil R. Gender-specific association of NFκBIA promoter polymorphisms with the risk of sporadic colorectal cancer. Med. Oncol. 2013, 30:693.
30. Thomas D.L., Astemborski J., Rai R.M., Anania F.A., Schaeffer M., Galai N., Nolt K., Nelson K.E., Strathdee S.A., Johnson L., Laeyendecker O., Boitnott J., Wilson L.E., Vlahov D. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
31. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
32. Wagoner J., Austin M., Green J., Imaizumi T., Casola A., Brasier A., Khabar K.S., Wakita T., Gale M., Polyak S.J. Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J. Virol. 2007, 81:309-318.
33. Waris G., Livolsi A., Imbert V., Peyron J.F., Siddiqui A. Hepatitis C virus NS5A and subgenomic replicon activate NF-kappaB via tyrosine phosphorylation of IkappaBalpha and its degradation by calpain protease. J. Biol. Chem. 2003, 278:40778-40787.
34. Yang X., Li P., Tao J., Qin C., Cao Q., Gu J., Deng X., Wang J., Liu X., Wang Z., Wu B., Gu M., Lu Q., Yin C. Association between NFκB1 -94ins/del ATTG promoter polymorphism and cancer susceptibility: an updated meta-analysis. Int. J. Genomics 2014, 2014:612972.
35. Zhao Z., Zhong X., Wu T., Yang T., Chen G., Xie X., Wei Y., Ye M., Zhou Y., Du Z. Identification of a NFκBIA polymorphism associated with lower NFκBIA protein levels and poor survival outcomes in patients with glioblastoma multiforme. Int. J. Mol. Med. 2014, 34:1233-1240.
36. Zou Y.F., Yuan F.L., Feng X.L., Tao J.H., Ding N., Pan F.M., Wang F. Association between NFκB1 -94ins/delATTG promoter polymorphism and cancer risk: a meta-analysis. Cancer Invest. 2011, 29:78-85.